Guided View New to genetics? We explain every term as you browse, in plain English. Same pages, with the help built in.
Expert View You already know the biology. Just the content, clean and compact, with no extra explanations. This is the default view.
Interface language
Light mode
Clinical trial · Hereditary angioedema
The Phase 1/2 study that took lonvo-z into late-stage development
Official title: A Study of NTLA-2002 in Adults With Hereditary Angioedema
CompletedPhase I/IINCT05120830
Clinical researchBeing tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.
What this trial is testing
The earlier trial of the hereditary angioedema treatment, testing whether a single infusion could reduce swelling attacks. Its results were published in a major medical journal and supported the move into the Phase 3 study that followed.
A Phase 1/2 study of NTLA-2002 in adults with hereditary angioedema, evaluating safety, pharmacodynamics and attack rate following a single dose. Results were published in the New England Journal of Medicine and supported progression to the Phase 3 HAELO study.
What a trial result does and does not mean
Early-phase results come from small numbers of participants and short follow-up. They can change with more people and more time, and a trial that is recruiting, active or even completed has not established that a treatment works. Enrolment criteria are strict; eligibility is decided by the trial site, never by a website.
Written by CRISPR Decoded editorial teamLast updated Oct 27, 2026
Connected in CRISPR Decoded
Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.
This link opens a website we do not run. We cannot control its content, its accuracy, or how it handles your data, including its own cookies and tracking. Nothing you read there has been reviewed by us.